B01AC13 - Abciximab

Not porphyrinogenic

Rationale

Polypeptide. No CYP-interactions.

Chemical description

Fab-fragment of the chimeric monoclonal antibody 7E3, binds to and blocks a platelet surface receptor. Used together with ASA and heparin as i.v. infusion 0.25 mg/kg BW, in percutaneous coronary intervention.

Similar drugs

Explore alternative drugs in similar therapeutic classes B01A / B01AC or go back.

References

Tradenames

Show more details and information about the listed tradenames

ReoPro

Reopro

Abciximab

In cooperation with IpNet

Acute Porphyria Drugs

B01AC13 - Abciximab